My Top 3 Dividend Kings to Buy for March 2026

AbbVie highlights pipeline depth with 90 drug/device candidates and continues dividend durability (54-year streak); Skyrizi generated $5.0B in Q4 (+32% YoY), Rinvoq $2.37B (+29.5%), Botox $3.76B in 2025, yield ~3%. Walmart reported $713B in sales for 2025, U.S. e-commerce +27% in Q1 FY2026, 53 consecutive years of dividend increases, a 0.8% yield and ~46% LTM share-price gain. Consolidated Edison plans $6.6B capex this year and $6.8B next year, reported 2025 net income $2.02B (EPS $5.66) vs $1.82B (EPS $5.26) in 2024, and offers a 3.1% yield with a 52-year dividend increase streak.

Analysis

AbbVie: breadth of candidates gives optionality, but the economics hinge on a small number of late-stage readouts and commercial execution over the next 6–24 months. A realistic scenario analysis shows binary upside if two phase-3 assets convert (20–40% free-cash-flow lift) versus a sharp hit to valuation if biosimilar/competitive uptake accelerates or pricing headwinds compress realized prices. Capital-allocation choices (dividends vs buybacks vs bolt-on M&A) will be the primary transmission mechanism to equity returns over the next 12–36 months.

Walmart/retail: e-commerce gains are a double-edged sword — they drive share gains but materially change margin and working-capital dynamics as fulfillment density and last-mile costs scale. The second-order winners are logistics/automation equipment suppliers and regional distribution landlords, while third-party marketplace operators face pricing pressure if Walmart pushes deeper private-label and fulfillment economics. Watch inventory turns and freight-cost trends over the next 2–6 quarters as leading indicators for margin re-acceleration or compression.

Utilities/ConEd: the ongoing transmission & distribution capex cycle creates multi-year regulated cash-flow visibility, but return realization is rate-case dependent and exposed to interest-rate drift and storm volatility. Contractors and equipment OEMs stand to benefit from multi-year spend, yet execution risk (permitting, labor, commodity inflation) can defer revenue recognition and increase financing needs — expect rate-case outcomes to be the primary catalysts on 6–18 month horizons.

Key Decisions for Investors

• Long ABBV (12–24 months) + protective puts: Buy ABBV equity, fund 12–18 month 20% OTM puts to cap downside from clinical/regulatory shocks. Risk/reward: dividend yield + 20–35% upside if late-stage assets read out positively; max loss limited to net premium if downside event occurs.
• Pair trade — Long WMT / Short a high-multiple e-commerce pure-play (9–12 months): Go long WMT equity on a <10% pullback vs recent highs and short a comparable-cap growth retailer to capture margin re-rating as omnichannel scale benefits winners. Risk/reward: target 15–25% gross return with pair hedge reducing market beta; stop-loss 12% on either leg.
• Rate-sensitive utility play (ED) — buy-and-income strategy (18–36 months): Accumulate ED on pullbacks >8% from highs and write 6–9 month covered calls to enhance carry while monitoring upcoming rate-case filings. Risk/reward: expected total return 8–12% annualized from regulated cash flow plus option premium; tail risk is >20% drawdown from adverse regulatory outcomes or extreme weather.
• Event-driven hedge — long large-cap pharma vs short small-cap biotech basket (12 months): Long a diversified large-cap pharma (ABBV) and short a basket of smaller, binary drug developers to capture wider dispersion if market de-risks. Risk/reward: asymmetric payoff if broad clinical successes consolidate into large-cap pricing, with max loss on short side managed via size limits and stop triggers.